Drug Trial Radar · NCT06641076
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
960
Planned (sponsor's estimate)
Start
Oct 15, 2024
Primary completion
May 28, 2026
Study completion Feb 4, 2027
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Conditions
- Arthritis, Psoriatic
Interventions
SonelokimabDrug
Randomized treatment, parallel-group
PlaceboDrug
Randomized treatment, parallel-group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Time frame: Week 16
Locations
182 sites in 20 countries. Site status is shown where the registry gives one.
Clinical Site
Avondale, Arizona
Clinical Site
Chandler, Arizona
Clinical Site
Flagstaff, Arizona
Clinical Site
Mesa, Arizona
Clinical Site
Phoenix, Arizona
Clinical Site
Scottsdale, Arizona
Clinical Site
Tucson, Arizona
Clinical Site
San Diego, California
Clinical Site
Upland, California
Clinical Site
Avon Park, Florida
Clinical Site
Clearwater, Florida
Clinical Site
Hialeah, Florida
Clinical Site
Tampa, Florida
Clinical Site
Springfield, Illinois
Clinical Site
Lake Charles, Louisiana
Clinical Site
Baltimore, Maryland
Clinical Site
Grand Blanc, Michigan
Clinical Site
Leland, North Carolina
Clinical Site
Salisbury, North Carolina
Clinical Site
Statesville, North Carolina
Clinical Site
Middleburg Heights, Ohio
Clinical Site
Portland, Oregon
Clinical Site
Memphis, Tennessee
Clinical Site
Allen, Texas
Clinical Site
Colleyville, Texas
Clinical Site
Lubbock, Texas
Clinical Site
Plano, Texas
Clinical Site
Beckley, West Virginia
Clinical Site
Pleven, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Calgary, Canada
Clinical Site
Trois-Rivières, Canada
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.